Woolsey Pharmaceuticals, Inc. news
NEW YORK, NY – January 3, 2021 – Woolsey Pharmaceuticals, a repurposed therapeutics development company announced that the European Medicines Agency’s Committee for Orphan Medicinal Product has issued a positive opinion on the orphan drug application for the Company’s investigational drug, BRAVYL® (oral fasudil), for the treatment of Amyotrophic Lateral Sclerosis (ALS). The opinion will be forwarded to the European Commission for a final
NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients.
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as motor neuron diseases. The estimated prevalence of ALS in the United
NEW YORK, NY – October 1, 2021 – Woolsey Pharmaceuticals announced today that it completed a second round of financing of $19.7 million. Proceeds will fund operations through the completion of Phase 2a clinical studies of BRAVYL for Wandering in Dementia, Progression Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis.
The Company also announced the appointment Rich Nelson as a board observer. Rich is the founder of Nelstone V
NEW YORK, February 18, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the first patient with BRAVYL in its FOUND (Fasudil fOr Uncontrolled waNDering) study for Alzheimer’s and Vascular Dementia patients who have wandering behaviors of elopement and/or getting lost. The Company also announced the first patient in its ROCKIT-1 (ROCK Inhibitor in Tauopathies – 1) trial of
NEW YORK, NY – March 11, 2020 – Woolsey Pharmaceuticals announced today that it completed a round of financing that will fund operations through the completion of a planned clinical study. The amount was not disclosed but the financing was substantially oversubscribed, according to company officials.
The Company also announced the appointment of two outside board members, David Epstein and Dr. Claude Piché.
David R. Epstein has more tha